The S-4/A filing advances the merger toward the stockholder vote. The key binary catalyst is the Rallybio stockholder meeting — if Proposals 1-3 pass, the merger closes and RLYB shares convert to AVZO at the exchange ratio. Monitor the vote outcome and any Nasdaq listing confirmation. The CVRs provide optionality on legacy asset monetization but are likely zero in a base case.
Price Chart
Executive Summary
Rallybio filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Avenzo Therapeutics, Inc. Under the Merger Agreement, Merger Sub will merge into Avenzo, with Avenzo surviving as a wholly owned subsidiary of Rallybio. Rallybio stockholders will retain their shares (subject to a reverse split) and receive a cash distribution of substantially all of Rallybio's net cash (estimated at ~$82.2M as of Aug 15, 2026) plus contingent value rights (CVRs) tied to legacy asset monetization. Avenzo equityholders and concurrent financing investors will receive ~97.2% of the combined company, with Rallybio pre-merger holders retaining ~2.8%.
Key Facts
- Merger expected to close in Q4 2026; Rallybio stockholders to vote on 9 proposals including stock issuance, reverse split (1:2 to 1:9), and name change to Avenzo Therapeutics, Inc.
- Pre-merger Rallybio equityholders expected to own ~2.8% of combined company; Avenzo equityholders ~56.6%; Concurrent Financing investors ~40.6% (based on $215M PIPE).
- Rallybio estimates Rallybio Net Cash of ~$82.2M as of Aug 15, 2026; substantially all to be distributed to pre-Closing Rallybio stockholders as Parent Distributions.
- Rallybio stockholders to receive one CVR per share for potential proceeds from legacy asset dispositions (through Dec 31, 2031).
- Combined company expected to trade on Nasdaq under symbol AVZO; listing condition may be waived.
- Avenzo has a going concern qualification with $324.4M accumulated deficit as of Jun 30, 2026.
- Rallybio had 5,312,584 shares outstanding as of Sep 11, 2026 record date; ~24.3% locked up via support agreements.
- Avenzo termination fee: $20M (or $8M after End Date); Rallybio termination fee: $600,000.
Financial Impact
Rallybio pre-merger holders get ~2.8% of combined company (~$530M implied value) plus ~$82.2M cash distribution and CVRs. Avenzo valued at $300M fixed; Rallybio valued at $15M. $215M concurrent PIPE adds ~40.6% ownership. Combined company implied value ~$530M.
Risk Factors
- Merger may fail if Rallybio stockholders do not approve required proposals (Nasdaq issuance, reverse split, name change).
- Parent Distribution amount is uncertain and may be materially less than estimated due to transaction expenses and liabilities.
- Combined company may not obtain Nasdaq listing; condition may be waived, creating delisting risk.
- Avenzo's going concern qualification and $324.4M accumulated deficit indicate high cash burn risk even after PIPE.
- CVRs may expire worthless if legacy assets are not monetized.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-421809 |
| Document: d71655dex991.htm | 0001193125-26-421809 |
| Document: d71655dex232.htm | 0001193125-26-421809 |
| Document: d71655dex231.htm | 0001193125-26-421809 |
| Document: 0001193125-26-421809-index-headers.html | 0001193125-26-421809 |
| Document: 0001193125-26-421809-index.html | 0001193125-26-421809 |
| Document: 0001193125-26-421809.txt | 0001193125-26-421809 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | — | awaiting T+60 | — | — |
Oct 26, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 16, 2026 10d ago | EFFECT | $16.28 | awaiting T+60 | — | $16.65 (+2.27%) |
Oct 14, 2026 12d ago | S-4/A | $16.78 | awaiting T+60 | — | $16.65 (−0.75%) |
Jul 15, 2026 14w ago | S-4 | $15.96 $17.02 | ▲ +6.64% | ▲ +2.93% | $16.65 (+4.32%) |
Jun 1, 2026 21w ago | 425 | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $16.65 (−1.30%) |
Jun 1, 2026 21w ago | 8-K | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $16.65 (−1.30%) |
May 4, 2026 25w ago | 8-K | $14.12 $15.96 | ▲ +13.03% | ▲ +11.17% | $16.65 (+17.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers